TP53 genetic alterations are highly recurrent in Epstein-Barr virus–negative aggressive NK-cell leukemia: insights from an institutional experience and comprehensive literature review
American Journal of Clinical Pathology · 2026
DOI: 10.1093/ajcp/aqag027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, 2026. Verfasst von Miguel Gonzalez Mancera und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Stanford, CA, United States. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Epstein-Barr Virus Infections, Leukemia, Large Granular Lymphocytic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objective
The differences between EBV-positive and EBV-negative aggressive NK-cell leukemia (ANKL) remain po orly understood. Herein, we sought to investigate the clinicopathologic and molecular differences between EBV-positive and EBV-negative ANKL.
Methods
We retrospectively analyzed 14 ANKL cases (9 EBV-positive, 5 EBV-negative), assessing clinicopathologic, cytogenetic, and mutational features. In addition, we searched the published literature to further analyze the distribution of genetic variation between EBV-positive (n=116) and EBV-negative-ANKL (n=14). Lastly, we assessed the utility of p53 immunohistochemistry to screen for EBV-negative-ANKL.
Results
Demographically, EBV-negative-ANKL patients were older (median age 64 vs. 37 years) and showed longer survival (median 13 vs. 1 month) than EBV-positive counterparts. Morphologic and immunophenotypic features were similar between groups. All EBV-negative cases assessed in our cohort harbored TP53 mutations (3/3). Combining our data with all reported ANKL cases with comprehensive mutational assessment of TP53, JAK/STAT and epigenetic modifier genes in the literature we find TP53 mutations or copy number alterations present in 82% of EBV-negative-ANKL (14/17) but in only 25% (29/116) of EBV-positive cases. In contrast, EBV-negative-ANKL showed less JAK/STAT and epigenetic modifier gene mutations compared to EBV-positive ANKL. Given the high frequency of TP53 genetic alteration, we show that p53 immunohistochemistry overexpression is present in all but one EBV-negative-ANKL case assessed thus far.
Conclusions
Our findings suggest that EBV-negative-ANKL is a distinct subtype of ANKL, highly enriched for TP53 genetic alterations and showing different epidemiologic and prognostic features compared to EBV-positive-ANKL. In addition, p53 immunohistochemistry may serve as a screening tool for EBV-negative-ANKL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Stanford, CA, United States.
ORCID-Profile: Yasodha Natkunam, Oscar Silva
Zitieren
APA
Gonzalez Mancera, M., Wilk, A. J., Oak, J., Natkunam, Y., & Silva, O. (2026). TP53 genetic alterations are highly recurrent in Epstein-Barr virus–negative aggressive NK-cell leukemia: insights from an institutional experience and comprehensive literature review. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqag027
Vancouver
Gonzalez Mancera M, Wilk AJ, Oak J, Natkunam Y, Silva O. TP53 genetic alterations are highly recurrent in Epstein-Barr virus–negative aggressive NK-cell leukemia: insights from an institutional experience and comprehensive literature review. American Journal of Clinical Pathology. 2026. doi:10.1093/ajcp/aqag027
BibTeX
@article{GonzalezMancera2026,
author = {Gonzalez Mancera, Miguel and Wilk, Aaron J and Oak, Jean and Natkunam, Yasodha and Silva, Oscar},
title = {TP53 genetic alterations are highly recurrent in Epstein-Barr virus–negative aggressive NK-cell leukemia: insights from an institutional experience and comprehensive literature review},
journal = {American Journal of Clinical Pathology},
year = {2026},
doi = {10.1093/ajcp/aqag027}
}
EUVIMED